XML 26 R12.htm IDEA: XBRL DOCUMENT v3.23.2
Inventory
 6 Months Ended
Jun. 30, 2023
Inventory Disclosure [Abstract]  
Inventory

3. Inventory

The following table presents our inventory (in thousands), all of which was related to XPOVIO:

 

 

 

As of June 30, 2023

 

 

As of December 31, 2022

 

Raw materials

 

$

1,124

 

 

$

1,370

 

Work in process

 

 

1,700

 

 

 

1,878

 

Finished goods

 

 

848

 

 

 

976

 

Total inventory

 

$

3,672

 

 

$

4,224

 

 

XPOVIO was initially approved by the FDA in July 2019 at which time we began to capitalize costs to manufacture XPOVIO. Prior to FDA approval of XPOVIO, all costs related to the manufacturing of XPOVIO and related material were charged to research and development expenses in the period incurred.